Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bio-Techne (TECH) EBITDA (2016 - 2025)

Bio-Techne has reported EBITDA over the past 17 years, most recently at $40.1 million for Q4 2025.

  • Quarterly results put EBITDA at $40.1 million for Q4 2025, up 329.51% from a year ago — trailing twelve months through Dec 2025 was $104.4 million (down 23.31% YoY), and the annual figure for FY2025 was $91.8 million, down 41.08%.
  • EBITDA for Q4 2025 was $40.1 million at Bio-Techne, up from $33.7 million in the prior quarter.
  • Over the last five years, EBITDA for TECH hit a ceiling of $84.9 million in Q4 2021 and a floor of $4.5 million in Q2 2025.
  • Median EBITDA over the past 5 years was $41.6 million (2022), compared with a mean of $46.9 million.
  • Peak annual rise in EBITDA hit 329.51% in 2025, while the deepest fall reached 88.04% in 2025.
  • Bio-Techne's EBITDA stood at $84.9 million in 2021, then decreased by 21.46% to $66.7 million in 2022, then plummeted by 37.29% to $41.8 million in 2023, then plummeted by 77.7% to $9.3 million in 2024, then skyrocketed by 329.51% to $40.1 million in 2025.
  • The last three reported values for EBITDA were $40.1 million (Q4 2025), $33.7 million (Q3 2025), and $4.5 million (Q2 2025) per Business Quant data.